#USA #gene therapy #Boulder, Colorado #KROMATID #genomic integrity

KROMATID Unveils Genomic Integrity Benchmarking at ASGCT 2026

A Transformative Advancement in Gene Therapy Assessment

KROMATID, a pioneering firm in genomic analysis, is gearing up to present a remarkable innovation at the upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. Scheduled for May 15, 2026, during the session on Analytics and Assay Development – Biosafety, KROMATID's presentation is set to reshape the landscape of genomic integrity assessments.

Abstract #ASGCT1713 - Title: Establishing chromosome-scale benchmarks for detecting genomic instability in gene-edited cell therapies using high-depth cytogenetic analysis.

The company will showcase a proprietary methodology that for the first time establishes chromosome-scale benchmarks essential for evaluating genomic instability. This unprecedented approach enables developers to clearly distinguish between normal and abnormal variants based on empirical data, dramatically transforming the static measure of genomic integrity into a dynamic framework that promotes informed decision-making.

Understanding KROMATID’s Breakthrough

As the gene therapy field advances, the complexity of therapies has outpaced traditional methods of analysis. KROMATID’s innovative use of high-depth cytogenetic analysis creates a roadmap for cell therapy developers by:

• - Providing benchmarks against chromosome-level standards.
• - Allowing contextual interpretation of structural variations detected.
• - Enhancing the confidence around safety, quality, and developmental decisions.
• - Offering clarity throughout the therapeutic lifecycle.

KROMATID's initiative not only sets a new industry standard but also heralds a significant shift towards integrating genomic intelligence. Terry Opgenorth, the CEO of KROMATID, encapsulates the vision: "This is a defining moment for cell and gene therapy. Our genomic intelligence platform brings clarity, context, and confidence to a space that has long operated without it. By reducing the risks associated with cell and gene therapy development, we aim to accelerate the market readiness of innovative therapies."

A New Era for Cell and Gene Therapy Developers

The implications of this breakthrough are vast. By enabling developers to contextualize their findings within a framework informed by data-driven benchmarks, the potential for enhancing the safety profiles of gene therapies grows exponentially. No longer are developers confined to analyzing isolated data points; they now have access to a new level of integrated genomic insights from discovery phases through regulatory approval to clinical development and commercial launch.

Visitors to ASGCT will have an opportunity to learn more about KROMATID’s advancements at Booth #1654. The team will be on hand to discuss the transformative impact of their genomic intelligence platform and how KROMATID can facilitate the success of cell and gene therapy initiatives.

About KROMATID

KROMATID stands at the forefront of next-gen genomic structural analysis designed specifically for cell and gene therapy developers. The company merges proprietary imaging techniques with advanced bioinformatics, enabling precise detection of chromosomal structural variations. Their work empowers developers to confidently navigate therapies from the initial discovery stages all the way through to regulatory approval. For more detailed information, KROMATID invites interested parties to visit their website at www.kromatid.com.

In conclusion, KROMATID's upcoming presentation at ASGCT 2026 not only signifies a leap forward in the realm of genomic integrity assessment but also promises to redefine how gene therapies are approached and evaluated in the modern medical landscape. Through this innovative platform, KROMATID aims to pave the way for safer and more effective treatments that could benefit countless patients around the globe.